Heska Corporation (HSKA)
| Market Cap | 2.36B |
| Revenue (ttm) | 227.17M |
| Net Income (ttm) | -7.24M |
| Shares Out | 9.48M |
| EPS (ttm) | -0.79 |
| PE Ratio | n/a |
| Forward PE | 243.90 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 22 |
| Last Price | $226.20 |
| Previous Close | $231.37 |
| Change ($) | -5.17 |
| Change (%) | -2.23% |
| Day's Open | 230.64 |
| Day's Range | 224.02 - 233.19 |
| Day's Volume | 88,478 |
| 52-Week Range | 81.98 - 233.60 |
LOVELAND, Colo., May 25, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, annou...
These seven small-cap stocks have the potential of rebounding and making it big in the post-pandemic reality of 2021. The post 7 Small-Cap Stocks To Buy for Their Big Ambitions appeared first on Investo...
Heska (HSKA) delivered earnings and revenue surprises of 555.56% and 11.48%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
LOVELAND, Colo., May 6, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading provider of advanced veterinary diagnostic and specialty products, reported financial resul...
LOVELAND, Colo., April 16, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska" or the "Company"), a leading provider of advanced veterinary diagnostic and specialty products, announces its 20...
LOVELAND, Colo., April 8, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading provider of advanced veterinary diagnostic and specialty products, will report its fi...
Heska has benefited from fast growth in the veterinary market, but should investors keep betting on the stock?
The pandemic puppy boom is real, and so are sales for these three pet stocks.
LOVELAND, Colo., March 2, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a leading provider of advanced veterinary diagnostic and specialty products, today annou...
LOVELAND, Colo., March 1, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a leading provider of advanced veterinary diagnostic and specialty products, today annou...
Shares of Heska (NASDAQ:HSKA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were up 928.57% over the past year to $0.72, which beat the estimate of ($0.22).
LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. J...
Heska Corporation's current financial performance illustrates the advantage of geographic spread very well. The benefit of scale and efficiency of HKSA's operations is evident in how neatly its geograph...
Heska Corporation (HSKA) CEO Kevin Wilson on Q3 2020 Results - Earnings Call Transcript
Heska (HSKA) delivered earnings and revenue surprises of 166.67% and 16.66%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heska's (HSKA) CEO Kevin Wilson on Q2 2020 Results - Earnings Call Transcript
Heska's (HSKA) CEO Kevin Wilson on Q1 2020 Results - Earnings Call Transcript
Heska (HSKA) delivered earnings and revenue surprises of 44.00% and -8.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Heska (NASDAQ:HSKA) remained unaffected at $70.17 after the company reported Q1 results.
But now, the agency isn't so sure about whether people can transmit the disease to dogs and cats.
Heska Corporation (HSKA) CEO Kevin Wilson on Q4 2019 Results - Earnings Call Transcript
Heska (HSKA) delivered earnings and revenue surprises of 133.33% and -1.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
See two of the featured stocks from this month’s model portfolios.
Heska Corporation (HSKA) CEO Kevin Wilson on Q3 2019 Results - Earnings Call Transcript
Heska (HSKA) delivered earnings and revenue surprises of 25.00% and 2.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Heska Corporation (HSKA) CEO Kevin Wilson on Q2 2019 Results - Earnings Call Transcript
Heska Corporation (HSKA) CEO Kevin Wilson on Q1 2019 Results - Earnings Call Transcript
About HSKA
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 30, 1997 |
| CEO Kevin Wilson | Employees 602 |
| Stock Exchange NASDAQ | Ticker Symbol HSKA |
Financial Performance
In 2020, HSKA's revenue was $197.32 million, an increase of 60.87% compared to the previous year's $122.66 million. Losses were -$14.40 million, 882.9% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for HSKA stock is "Buy." The 12-month stock price forecast is 221.75, which is a decrease of -1.97% from the latest price.